Alcon (ALC) DeferredTaxAndRevenue

: $78 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Alcon's current deferred tax and revenue for the quarter that ended in Dec. 2023 was $78 Mil.

Alcon DeferredTaxAndRevenue Historical Data

The historical data trend for Alcon's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alcon Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

DeferredTaxAndRevenue

97.00

110.00

108.00

89.00

78.00

Alcon Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
DeferredTaxAndRevenue																89.00	-	-	-	78.00

Alcon DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Alcon's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Alcon (ALC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Alcon Inc (NYSE:ALC) » Definitions » DeferredTaxAndRevenue

Comparable Companies

Traded in Other Exchanges

ALC:Mexico ALCz:UK 0A0D:UK ALC:Switzerland

Address

Chemin de Blandonnet 8, Royce Bedward, Vernier, Geneva, CHE, 1214

Website

https://www.alcon.com

Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls one fourth of the U.S. contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.